EP3082427A4 - Compositions and methods for treatment of glaucoma - Google Patents

Compositions and methods for treatment of glaucoma Download PDF

Info

Publication number
EP3082427A4
EP3082427A4 EP14872240.8A EP14872240A EP3082427A4 EP 3082427 A4 EP3082427 A4 EP 3082427A4 EP 14872240 A EP14872240 A EP 14872240A EP 3082427 A4 EP3082427 A4 EP 3082427A4
Authority
EP
European Patent Office
Prior art keywords
glaucoma
compositions
treatment
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP14872240.8A
Other languages
German (de)
French (fr)
Other versions
EP3082427A1 (en
Inventor
Gerald Horn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GNT LLC
Original Assignee
GNT LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/132,780 external-priority patent/US20140107173A1/en
Application filed by GNT LLC filed Critical GNT LLC
Publication of EP3082427A1 publication Critical patent/EP3082427A1/en
Publication of EP3082427A4 publication Critical patent/EP3082427A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/4174Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP14872240.8A 2013-12-18 2014-02-11 Compositions and methods for treatment of glaucoma Withdrawn EP3082427A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14/132,780 US20140107173A1 (en) 2011-02-03 2013-12-18 Compositions and Methods for Treatment of Glaucoma
PCT/US2014/015797 WO2015094392A1 (en) 2013-12-18 2014-02-11 Compositions and methods for treatment of glaucoma

Publications (2)

Publication Number Publication Date
EP3082427A1 EP3082427A1 (en) 2016-10-26
EP3082427A4 true EP3082427A4 (en) 2017-08-02

Family

ID=53403464

Family Applications (1)

Application Number Title Priority Date Filing Date
EP14872240.8A Withdrawn EP3082427A4 (en) 2013-12-18 2014-02-11 Compositions and methods for treatment of glaucoma

Country Status (7)

Country Link
EP (1) EP3082427A4 (en)
JP (1) JP2017501224A (en)
CN (1) CN106455567A (en)
BR (1) BR112016014404A2 (en)
CA (1) CA2934453A1 (en)
MX (1) MX2016007902A (en)
WO (1) WO2015094392A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108883102A (en) * 2016-03-17 2018-11-23 远视眼治疗有限责任公司 For treating the composition and method of farsightedness
US20210251970A1 (en) 2018-10-10 2021-08-19 Presbyopia Therapies Inc Compositions and methods for storage stable ophthalmic drugs
CN111481506B (en) * 2019-01-25 2023-01-24 江苏恒瑞医药股份有限公司 Pharmaceutical product comprising a nasally administrable dexmedetomidine composition
CN116474219A (en) * 2019-06-28 2023-07-25 四川普锐特药业有限公司 Drug fluid dispenser and dexmedetomidine nasal spray for maintaining uniformity of administration
CN112107544A (en) * 2019-06-28 2020-12-22 四川普锐特药业有限公司 Dexmedetomidine nasal spray, preparation method and application thereof
CN111632025A (en) * 2020-03-04 2020-09-08 吉林大学第一医院 A kind of bimeprost ophthalmic temperature-sensitive in situ gel and its preparation method and application
CN115137699B (en) * 2021-03-29 2024-05-03 四川普锐特药业有限公司 A dexmedetomidine nasal spray with enhanced efficacy and preservation
US12180206B2 (en) 2021-11-17 2024-12-31 Lenz Therapeutics Operations, Inc. Aceclidine derivatives, compositions thereof and methods of use thereof
US12414942B1 (en) 2024-03-15 2025-09-16 Lenz Therapeutics Operations, Inc. Compositions, methods, and systems for treating presbyopia

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012106537A1 (en) * 2011-02-03 2012-08-09 Alpha Synergy Development, Inc. Compositions and methods for treatment of glaucoma
US20130172357A1 (en) * 2011-02-03 2013-07-04 Eye Therapies Llc Compositions and Methods for Treatment of Glaucoma
WO2013115844A1 (en) * 2012-02-02 2013-08-08 Alpha Synergy Development, Inc. Compositions and methods for treatment of glaucoma
WO2014204791A1 (en) * 2013-06-21 2014-12-24 Gnt, Llc Ophthalmic lipophilic and hydrophilic drug delivery vehicle formulations
WO2015031186A1 (en) * 2013-08-28 2015-03-05 Presbyopia Theraplies, Llc Compositions and methods for the treatment of presbyopia

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2290964A (en) * 1994-07-08 1996-01-17 Arto Olavi Urtti Transdermal drug delivery system
CA2534484A1 (en) * 2003-08-07 2005-02-17 Allergan, Inc. Compositions for delivery of therapeutics into the eyes and methods for making and using same
US20100202979A1 (en) * 2008-08-01 2010-08-12 Gerald Horn Compositions and methods for treatment of pulmonary diseases and conditions
US20100028266A1 (en) * 2008-08-01 2010-02-04 Alpha Synergy Development. Inc. Composition and methods for treating allergic response
US20110152271A1 (en) * 2009-12-17 2011-06-23 Gerald Horn Compositions and methods for ophthalmic delivery of nasal decongestants
US20110189174A1 (en) * 2010-02-01 2011-08-04 Afshin Shafiee Compositions and methods for treating, reducing, ameliorating, alleviating, or inhibiting progression of, pathogenic ocular neovascularization
WO2011127151A2 (en) * 2010-04-07 2011-10-13 Allergan, Inc. Combinations of preservatives for ophthalmic compositions
US20140107173A1 (en) * 2011-02-03 2014-04-17 Gnt, Llc Compositions and Methods for Treatment of Glaucoma
CN103796652A (en) * 2011-07-14 2014-05-14 阿勒根公司 Gel compositions of oxymetazoline and methods of use
US8242158B1 (en) * 2012-01-04 2012-08-14 Hospira, Inc. Dexmedetomidine premix formulation

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012106537A1 (en) * 2011-02-03 2012-08-09 Alpha Synergy Development, Inc. Compositions and methods for treatment of glaucoma
US20130172357A1 (en) * 2011-02-03 2013-07-04 Eye Therapies Llc Compositions and Methods for Treatment of Glaucoma
WO2013115844A1 (en) * 2012-02-02 2013-08-08 Alpha Synergy Development, Inc. Compositions and methods for treatment of glaucoma
WO2014204791A1 (en) * 2013-06-21 2014-12-24 Gnt, Llc Ophthalmic lipophilic and hydrophilic drug delivery vehicle formulations
WO2015031186A1 (en) * 2013-08-28 2015-03-05 Presbyopia Theraplies, Llc Compositions and methods for the treatment of presbyopia

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2015094392A1 *

Also Published As

Publication number Publication date
BR112016014404A2 (en) 2017-08-08
MX2016007902A (en) 2016-10-28
CN106455567A (en) 2017-02-22
CA2934453A1 (en) 2015-06-25
EP3082427A1 (en) 2016-10-26
WO2015094392A1 (en) 2015-06-25
JP2017501224A (en) 2017-01-12

Similar Documents

Publication Publication Date Title
EP3038610A4 (en) Compositions and methods for the treatment of presbyopia
EP3049070A4 (en) Compositions and methods for treatment and prophylaxis of gastrointestinal diseases
EP3024497A4 (en) Methods and compositions for treating brain diseases
EP2997146A4 (en) Methods and compositions for treatment of a genetic condition
EP3071193A4 (en) Compositions and methods for treatment of ocular inflammation and pain
EP3038646A4 (en) Diagnostic methods and compositions for treatment of glioblastoma
EP3082819A4 (en) Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewith
EP2991946A4 (en) Pumice-containing remedial compositions and methods of use
EP2958936A4 (en) Methods and compositions for treatment of forbes-cori disease
EP2967049A4 (en) Methods, compounds, and compositions for the treatment of angiotensin-related diseases
EP3021839A4 (en) Methods and compositions for treatment of fibrosis
EP2986113A4 (en) Compositions and methods for the treatment of brain injury
EP3086809A4 (en) Compositions and methods of treating ocular diseases
EP3046581A4 (en) Compositions and methods for treatment of hsct-associated thrombotic microangiopathy
EP3082427A4 (en) Compositions and methods for treatment of glaucoma
EP3004396A4 (en) Methods and compositions for the treatment of cancer
EP3057596A4 (en) Compositions and methods of administering same
EP3082845A4 (en) Methods and compositions for treatment of peripheral neuropathies
EP3021840A4 (en) Methods and compositions for prevention of allergic reaction
PL2968478T3 (en) Compositions and methods for the treatment of carboxyhemoglobinemia
IL245373A0 (en) Treatment of glaucoma using laquinimod
EP3043817A4 (en) Methods and compositions for treatment of chlamydial infection and related diseases and disorders
EP3068431A4 (en) Methods and compositions for the treatment of hcmv
EP2994147A4 (en) Compositions and methods for the treatment of tinnitus
EP3038596A4 (en) Compositions and methods for the removal of tattoos

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20160617

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20170705

RIC1 Information provided on ipc code assigned before grant

Ipc: A01N 43/56 20060101AFI20170629BHEP

Ipc: A61K 9/00 20060101ALI20170629BHEP

Ipc: A61K 31/415 20060101ALI20170629BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20180201